

# ADVANCED PROSTATE CANCER - HOW DO WE MOVE FORWARD IN PATIENT MANAGEMENT?

Available on-demand from Monday 14 September 2020 09:00 CEST at the ESMO Virtual Congress 2020

## SCIENTIFIC COMMITTEE

Eleni Efstathiou **USA**  
Boris Hadaschik **GERMANY**

## FACULTY

Elena Castro **SPAIN**  
Kim Chi **CANADA**  
Nicolas Mottet **FRANCE**

This exciting symposium will be pre-recorded, but don't miss out the opportunity to join our live Q&A session on Friday 18 September 17:00-18:00 CEST and ask your questions to the faculty.

## OVERALL LEARNING OBJECTIVES

After attending this symposium, participants should be able to:

- Review the current management strategies for metastatic hormone-sensitive prostate cancer (mHSPC) to optimise patient care
- Discuss the impact of new data on treatment and management decisions for individual patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-resistant prostate cancer (mCRPC)
- Describe considerations for managing patients with prostate cancer during the COVID-19 pandemic

## PROGRAM

SESSION	FACULTY
Welcome and introduction	Boris Hadaschik
Optimising care for individual patients with mHSPC	Kim Chi and Eleni Efstathiou
nmCRPC: Translating benefit to clinical practice	Elena Castro and Boris Hadaschik
Choosing the right pathway in the current and future management of mCRPC	
Flattening the curve: Consequences for the management of prostate cancer in the ongoing COVID-19 pandemic	Nicolas Mottet and Eleni Efstathiou
Concluding remarks	Eleni Efstathiou